PRAX Praxis Precision Medicines Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PRAX

Price (delayed)

$265.39

Market cap

$7.4B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$13.38

Enterprise value

$6.86B

?
Relative Growth: Rel. Growth: 4
Relative Strength: Rel. Strength: 98
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 4

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights ...

Highlights
The quick ratio has soared by 89% year-on-year and by 56% since the previous quarter
PRAX's equity has soared by 61% from the previous quarter
The gross profit has dropped by 100% year-on-year
The revenue has dropped by 100% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://praxismedicines.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of PRAX

PRAX stock price

How has the Praxis Precision Medicines stock price performed over time
Intraday
-4.85%
1 week
-24.74%
1 month
-21.39%
1 year
541.5%
YTD
-9.96%
QTD
-17.63%

Financial performance

How have Praxis Precision Medicines's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$357.33M
Net income
-$326.53M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% year-on-year
The revenue has dropped by 100% year-on-year
The net income has plunged by 54% YoY and by 8% from the previous quarter
The operating income has dropped by 53% year-on-year and by 10% since the previous quarter

Price vs fundamentals

How does PRAX's price correlate with its fundamentals

Growth

What is Praxis Precision Medicines's growth rate over time

Valuation

What is Praxis Precision Medicines stock price valuation
P/E
N/A
P/B
5.24
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
PRAX's EPS is down by 24% year-on-year
PRAX's P/B is 104% above its 5-year quarterly average of 2.7 and 10% above its last 4 quarters average of 5.0
PRAX's equity has soared by 61% from the previous quarter
The revenue has dropped by 100% year-on-year

Efficiency

How efficient is Praxis Precision Medicines business performance
Praxis Precision Medicines's ROE has increased by 27% from the previous quarter and by 15% YoY
The company's return on invested capital rose by 27% QoQ and by 16% YoY
Praxis Precision Medicines's ROA has increased by 25% from the previous quarter and by 14% YoY

Dividends

What is PRAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PRAX.

Financial health

How did Praxis Precision Medicines financials performed over time
The quick ratio has soared by 89% year-on-year and by 56% since the previous quarter
PRAX's current ratio has surged by 88% year-on-year and by 55% since the previous quarter
The debt is 100% smaller than the equity
PRAX's equity has soared by 61% from the previous quarter
The debt has increased by 35% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.